Septerna

Historical price data

Septerna leverages its industrial-scale Native Complex Platform® to unlock previously difficult-to-drug GPCRs, a target class accounting for one-third of all FDA-approved drugs but with 75% of its therapeutic potential still untapped. The company has built a wholly-owned pipeline of oral small molecule programs, with its lead asset SEP-631 (MRGPRX2 NAM) showing positive Phase 1 data and entering Phase 2 for chronic spontaneous urticaria. Septerna's strategy combines independent development of programs in endocrinology and immunology with selective partnerships for metabolic programs, positioning it to develop the next generation of impactful GPCR-targeted medicines.

Native Complex Platform® - proprietary technology to isolate, purify, and reconstitute GPCRs outside of cells into native complexes with ligands, transducer proteins, and lipid bilayers, enabling high-resolution structure determination and industrial-scale drug discovery.

2 drugs in pipeline

Total raised: $200M

Septerna competes with large pharmaceutical companies with internal GPCR programs and specialized GPCR biotechs like Sosei Heptares. Its differentiation lies in the unique Native Complex Platform®, industrial-scale capabilities, focus on oral small molecules, foundational science from Nobel laureate founders, and ability to develop diverse pharmacologies including allosteric modulators.